Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chugai Announced New Mid-Term “Sunrise 2012” Plan

This article was originally published in PharmAsia News

Executive Summary

Chugai President Naoru Nagayama announced a new mid-term business plan, Sunrise 2012, at a Jan. 30 briefing to stave off a lowered profit target from ¥100 billion to ¥80 billion. He said he is still optimistic about maximum value generation from the company's new products, and that its alliance with Roche has reinforced its cancer drug pipeline. In 2007, three new products - Avastin, Tarceva and Copegus went on sale. Chugai's IL-6 receptor antibody Actemra also was submitted for approval overseas. Nagayama said these developments indicated the portfolio is bearing fruit. Chugai will also strengthen marketing and sales operations, and will set up a portfolio management committee and strategic marketing committee, aiming to defend market shares for current products and realize maximum valuation for new cancer treatments. (Click for more-Japanese language

You may also be interested in...



People On The Move: Appointments At Sanofi, Enzymatica And Bayer

Sanofi has named the head of its new API business; Sweden's Enzymatica has hired talent from J&J and L'Oreal; and Bayer has a new transformation officer.

Trust, Innovation And Growth – Three Priorities For The Global Self-Care Industry In 2021

The Global Self-Care Federation is looking to consolidate the shift towards self-care seen during the pandemic by promoting trust, innovation and growth in policy. An upcoming webinar hosted by the GSCF will also explore the theme of "Advancing Trust in the Self-Care Industry."

After Ups and Downs, Industry Attempts To Normalize In Q3

After seeing a spike in demand due to the coronavirus pandemic in Q1, with a corresponding dip in Q2, the generics industry has largely seen single-digit drops in net revenues in the third quarter of 2020. Meanwhile, the Indian pharma market has seen recovery after facing a challenging coronavirus-induced slump in the first two quarters of 2020.

UsernamePublicRestriction

Register

LL1135415

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel